[별지 제65호의48서식]

SUBMISSION OF AMENDMENTS

To : Commissioner of
the Korean Intellectual Property Office

International Application No.	PCT/KR2002/001975	International Filing Date	22 October 2002 (22.10.2002)	Priority Date	19 April 2002 (19.04.2002)	
Applicant	Name	REGEN BIOTECH, INC. et al.	Residence Reg. No.		Country of Nationality	KR
	Address	C9231 KIST, 39-1 Hawolgok-dong, Sungbuk-ku 136-791 Seoul Republic of Korea				
Agent	Name	LEE, Won-Hee	Agent's Code	9-1998-000385-9	Tel. No.	82-2-3453-0507
	Address	8th Fl., Sung-ji Heights II, 642-16, Yoksam-dong, Kangnam-ku, 135-080 Seoul Republic of Korea				

☐ Submitted hereby is a correction pursuant to Article 106-33(2) of the Enforcement Regulations of the Patent Law.

☑ Submitted hereby is a correction pursuant to Article 106-36(3) of the Enforcement Regulations of the Patent Law.

☐ Submitted hereby is a correction pursuant to Article 106-40(6) of the Enforcement Regulations of the Patent Law.

Date(day/month/year) 09 September 2004 (09. 09. 2004)

Applicant(Agent) LEE, Won-Hee (Seal)

※ Attached Document(s) :

1. Two copies of written amendments
2. A statement explaining the amendments and its reason
3. A copy of the document(s) substantiating the power of attorney, if any

What is Claimed is

1. (amended) A method for measuring the amount of β ig-h3 protein comprises the following steps:
   1) Preparing recombinant β ig-h3 proteins comprising 4th fas-1 domains, their fragments or derivatives, as standard proteins;
   2) Preparing specific ligands against the above recombinant proteins, their fragments or derivatives of the above step 1; and
   3) Measuring the amount of β ig-h3 protein of samples with the method using binding reaction of ligands of the above step 2 with the recombinant proteins, their fragments or derivatives of the above step 1.

2. The method for measuring the amount of β ig-h3 protein as set forth in claim 1, wherein the ligands of step 1) are selected from a group consisting of antibodies, RNA, DNA, lipids, proteins, organic compounds and inorganic compounds.

3. The method for measuring the amount of β ig-h3 protein as set forth in claim 1, wherein the

specific binding reaction of step 3) is antigen-antibody reaction.

4. The method for measuring the amount of β ig-h3 protein as set forth in claim 3, wherein the antigen-antibody reaction is performed by a method selected from a group consisting of immunoblotting, immunoprecipitation, ELISA, RIA, protein chip, rapid assay and microarray.

5. (amended) The method for measuring the amount of β ig-h3 protein as set forth in claim 3, wherein the antigen-antibody reaction of step 3) comprises the following steps:

1) Coating recombinant β ig-h3 proteins comprising 4^{th} fas-1 domains, their fragments or derivatives to matrix;

2) Reacting antibody against the protein of the above step 1, its fragments or derivatives with sample;

3) Adding the reactant of the above step 2 to the coated protein of step 1 and waiting for reaction, and then washing thereof; and

4) Adding the secondary antibody to the reactant of the above step 3 for further reaction, and then measuring OD.

6. The method for measuring the amount of β ig-h3 protein as set forth in anyone of claim 1-5, wherein the β ig-h3 protein is human β ig-h3 protein having amino acid sequence represented by SEQ. ID. NO 3 or mouse β ig-h3 protein having amino acid sequence represented by SEQ. ID. No 5.

7. (amended) The method for measuring the amount of β ig-h3 protein as set forth in anyone of claim 1-5, wherein the recombinant β ig-h3 proteins comprising 4^{th} fas-1 domains have 1-10 repeatedly-linked fas-1 domains.

8. The method for measuring the amount of β ig-h3 protein as set forth in claim 7, wherein the fas-1 domain of β ig-h3 is selected from a group consisting of sequences represented by SEQ. ID. No 7, No 8, No 9 and No 10.

9. The method for measuring the amount of β ig-h3 protein as set forth in claim 1, wherein the sample can be any body fluid including urine, blood or synovial fluid.

10. A diagnostic kit for the renal diseases, hepatic

diseases, rheumatoid arthritis or cardiovascular diseases comprising β ig-h3 protein or recombinant proteins of fas-1 domain in the β ig-h3 protein (including their fragments or their derivatives) and their ligands.

11. The diagnostic kit as set forth in claim 10, wherein the ligand is selected from a group consisting of antibody specifically binding to β ig-h3 protein, fas-1 domain of β ig-h3, their fragments or derivatives, RNA, DNA, lipids, proteins, organic compounds and inorganic compounds.

12. The diagnostic kit as set forth in claim 11, wherein the ligand is antibody.

13. The diagnostic kit as set forth in claim 12, wherein the kit additionally includes buffer solution, secondary antibody, washing solution, stop solution or coloring substrate.

14. The diagnostic kit as set forth in claim 10, wherein the β ig-h3 protein is human β ig-h3 protein having amino acid sequence represented by SEQ. ID. No 3 or mouse β ig-h3 protein having

amino acid sequence represented by SEQ. ID. No 5.

15. The diagnostic kit as set forth in claim 10, wherein 1 or 2-10 4th fas-1 domains of β ig-h3 protein are repeatedly linked.

16. The diagnostic kit as set forth in claim 15, wherein the fas-1 domain of β ig-h3 is selected from a group consisting of sequences represented by SEQ. ID. No 7, No 8, No 9 and No 10.